Carboxylate ligand modified ferric iron hydroxide compositions for use in the treatment or prevention of iron deficiency associated with liver diseases
US12329736B2 · kind B2 · utility
0Cited by
2References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2021 |
| Grant date | Jun 17, 2025 |
| Priority date | — |
| Expiry date | Feb 16, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of carboxylate ligand modified ferric iron hydroxide compositions for the treatment or prevention of iron deficiency associated with liver diseases is disclosed, and more particularly to the class of Iron Hydroxide Adipate Tartrate (IHAT) materials for 10 use in the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.